BUZZ-Viatris slumps after weaker-than-expected earnings forecast

Shares of generic drugmaker Viatris VTRS.O fall 11.3% to $9.97 premarket

Co forecast 2025 revenue to be between $13.5 bln and $14 bln, below analysts' est of $14.27 bln - LSEG

Co expects 2025 adj profit between $2.12/shr and $2.26/shr, compared with estimates of $2.59/shr - LSEG

VTRS says it estimates FDA action will negatively impact its 2025 total revenues by about $500 mln and adjusted core earnings by roughly $385 mln.

Last year, FDA has restricted imports from Viatris' Indore facility in India due to regulatory violations

Co also reports Q4 adj profit of 54 cents/shr, below analysts' est of 57 cents/shr - LSEG

Co posts Q4 sales of $3.52 bln, below analysts' est of $3.61 bln - LSEG

VTRS gained 8.6% in 2024